A Clinical Prospective Study to Validate a Risk Scoring Model for the Hepatic Metastases From Gastric Cancer After Curative Surgery
Conditions: Predictive Cancer Model, Hepatic Metastasis, Gastric Cancer
Sponsor: Tianjin Medical University Cancer Institute and Hospital

 
 
 
 
A clinical prospective study to validate a risk scoring model for the 
hepatic metastases from gastric cancer after curative surgery 
（DJY003 Trail） 
 
 
 
 
Edition Number： 1.0 
Edition Generation Date： Apr 29, 2023 
Principal Investigator： Jingyu Deng  
Research Institute： Cancer Hospital & Institute of Tianjin Medical University 
ClinicalTrials.gov ID:  NCT06023966 
 

Protocol: 
 
Patients included in the study 
N=120 
– 
Curative gastrectomy and D2 lymphadenectomy 
– 
Postoperative pathology confirmed gastric cancer without distant metastasis, distant lymph node 
metastasis or peritoneal dissemination (M0) 
– 
Age between 18 and 70 years 
– 
KPS score >60 
– 
No liver occupying disease and other chronic diseases of the liver prior to curative surgery  
– 
No seriously chronic diseases of important organs 
Postoperative observation and follow-up 
With hepatic metastases 
Without hepatic metastases 
To analyze the consistency between the actual results of postoperative hepatic 
metastases occurrence and the predicted results by the risk scoring model to 
identify the clinical applicability of the model, not only for patients not receiving 
preoperative neoadjuvant therapy, but also for those receiving such therapy. 
To further explore the impact of neoadjuvant therapy and its efficacy (TRG0-1 vs 
TRG2-3) on the risk and interval of postoperative hepatic metastases.